Precision for Medicine

Research groups and companies are developing and applying tools to enrich for and capture CTCs to diagnose tumors early and monitor patients during treatment.

The move will gain PFM a Houston lab, as well as ApoCell's proprietary ApoStream liquid biopsy technology for isolation and capture of circulating tumor cells.

The deal provides Precision for Medicine with a proprietary PCR-based technology that amplifies and detects euchromatic DNA expressed exclusively by cell types of interest.

The deal joins Precision for Medicine's suite of biomedical research tools and services with ACT Oncology's expertise in clinical study design and execution.

PATH is designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

CEOs at four of the five leading mass spec firms saw their total compensation dip last year, according to information provided in their proxy statements, with Bill Sullivan at Agilent taking the biggest hit, a 39 percent drop from his 2007 earnings. Meanwhile, Frank Laukien at Bruker received an 80 percent upgrade in 2008.

Chinese state news agency Xinhua reports that a preliminary investigation has found He Jiankui performed his gene-editing work illegally.

John Mendelsohn, a former president of the University of Texas MD Anderson Cancer Center, has died, the New York Times reports.

Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.

In PNAS this week: chromosomal features of maize, adaptations in the vinous-throated parrotbill, and more.